Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4343-4346

  Bulman, Zackery P ^a   Sutton, Mark D ^c   Ly, Neang S ^a   Bulitta, Jurgen B ^a,b   Holden, Patricia N ^a   Nation, Roger L ^b   Li, Jian ^b   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL VIRULENCE; BROTH DILUTION; DNA REPAIR; GALLERIA MELLONELLA; GROWTH REGULATION; NONHUMAN; PATHOGENICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SURVIVAL TIME; ANIMAL; ANTIBIOTIC RESISTANCE; CYSTIC FIBROSIS; DRUG EFFECTS; GENETICS; KAPLAN MEIER METHOD; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOTH; MUTATION; PSEUDOMONAS INFECTIONS; SURVIVAL; SURVIVAL ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DNA REPAIR; DRUG RESISTANCE, BACTERIAL; KAPLAN-MEIER ESTIMATE; MICROBIAL SENSITIVITY TESTS; MOTHS; MUTATION; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL; SURVIVAL ANALYSIS;

EID: 84935896720     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04629-14     Document Type: Article

References (22)

1. He J, Baldini RL, Deziel E, Saucier M, Zhang Q, Liberati NT, Lee D, Urbach J, Goodman HM, Rahme LG. 2004. The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci U S A 101:2530-2535. http://dx.doi.org/10.1073/pnas.0304622101.
2. Wong A, Rodrigue N, Kassen R. 2012. Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Genet 8:e1002928. http://dx.doi.org/10.1371/journal.pgen.1002928.
3. Gooderham WJ, Hancock RE. 2009. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev 33:279-294. http://dx.doi.org/10.1111/j.1574-6976.2008.00135.x.
4. Pearson JP, Gray KM, Passador L, Tucker KD, Eberhard A, Iglewski BH, Greenberg EP. 1994. Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes. Proc Natl Acad Sci USA91:197-201. http://dx.doi.org/10.1073/pnas.91.1.197.
5. Kadurugamuwa JL, Beveridge TJ. 1995. Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion. J Bacteriol 177:3998-4008.
6. Sonstein SA, Burnham JC. 1993. Effect of low concentrations of quinolone antibiotics on bacterial virulence mechanisms. Diagn Microbiol Infect Dis 16:277-289. http://dx.doi.org/10.1016/0732-8893(93)90078-L.
7. Tateda K, Comte R, Pechere J-C, Köhler T, Yamaguchi K, Van Delden C. 2001. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45:1930-1933. http://dx.doi.org/10.1128/AAC.45.6.1930-1933.2001.
8. Sanders LH, Devadoss B, Raja GV, O'Connor J, Su S, Wozniak DJ, Hassett DJ, Berdis AJ, Sutton MD. 2011. Epistatic roles for Pseudomonas aeruginosa MutS and DinB (DNA Pol IV) in coping with reactive oxygen species-induced DNA damage. PLoS One 6:e18824. http://dx.doi.org/10.1371/journal.pone.0018824.
9. Fujitani S, Sun HY, Yu VL, Weingarten JA. 2011. Pneumonia due to Pseudomonas aeruginosa. Part I. Epidemiology, clinical diagnosis, and source. Chest 139:909-919. http://dx.doi.org/10.1378/chest.10-0166.
10. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1253. http://dx.doi.org/10.1126/science.288.5469.1251.
11. Henwood CJ, Livermore DM, James D, Warner M, Pseudomonas Study Group. 2001. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother 47:789-799. http://dx.doi.org/10.1093/jac/47.6.789.
12. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34:634-640. http://dx.doi.org/10.1086/338782.
13. Sanders LH, Sudhakaran J, Sutton MD. 2009. The GO system prevents ROS-induced mutagenesis and killing in Pseudomonas aeruginosa. FEMS Microbiol Lett 294:89-96. http://dx.doi.org/10.1111/j.1574-6968.2009.01550.x.
14. th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Tsuji BT, von Eiff C, Kelchlin PA, Forrest A, Smith PF. 2008. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother 52:1533-1537. http://dx.doi.org/10.1128/AAC.01254-07.
16. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC, Jr, Eliopoulos GM. 2009. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis 199:532-536. http://dx.doi.org/10.1086/596511.
17. Gales AC, Reis AO, Jones RN. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39:183-190. http://dx.doi.org/10.1128/JCM.39.1.183-190.2001.
18. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL, Oliver A. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49:3382-3386. http://dx.doi.org/10.1128/AAC.49.8.3382-3386.2005.
19. Canfield GS, Schwingel JM, Foley MH, Vore KL, Boonanantanasarn K, Gill AL, Sutton MD, Gill SR. 2013. Evolution in fast forward: a potential role for mutators in accelerating Staphylococcus aureus pathoadaptation. J Bacteriol 195:615-628. http://dx.doi.org/10.1128/JB.00733-12.
20. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A. 2012. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog 8:e1002505. http://dx.doi.org/10.1371/journal.ppat.1002505.
21. Banerjee D, Stableforth D. 2000. The treatment of respiratory Pseudomonas infection in cystic fibrosis. Drugs 60:1053-1064. http://dx.doi.org/10.2165/00003495-200060050-00006.
22. Szaff M, Høiby N, Flensborg E. 1983. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Pædiatr 72:651-657.